Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes

Anti-vascular endothelial growth factor (Anti-VEGF) agents are the standard of care for diabetic macular edema (CI-DME) with vision loss. They are commonly administered using several treatment protocols, including fixed, pro re nata (PRN) and treat-and-extend (T&E) regimens. Because of the lack...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Survey of ophthalmology 2022-09, Vol.67 (5), p.1346-1363
Hauptverfasser:	Sarohia, Gurkaran S., Nanji, Keean, Khan, Mohammad, Khalid, Muhammad F., Rosenberg, Daniel, Deonarain, Deven M., Phillips, Mark R., Thabane, Lehana, Kaiser, Peter K., Garg, Sunir J., Sivaprasad, Sobha, Wykoff, Charles C., Chaudhary, Varun
Format:	Artikel
Sprache:	eng
Schlagworte:	Aflibercept Diabetes Diabetic macular edema Diabetic retinopathy Faricimab Intravitreal anti-VEGF Ranibizumab Retina Vascular endothelial growth factor VEGF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!